P53、C-MYC和BCL-6基因异常在弥漫性大B细胞淋巴瘤中的临床意义

Clinical Significance of P53、C-MYC and BCL-6 Abnormality in Patients with Diffuse Large B Cell Lymphoma

目的:研究P53.C Bbl YC和BCL-6基因异常在弥漫性大B细胞淋巴瘤(DLBCL)中的临床意义。方法:选取2011年7月至2013年1月期间收治的80例弥漫性大B细胞淋巴瘤患者作为研究对象,收集患者临床资料并采用间期荧光原位杂交(I-FISH)检测P53.C-MYC和BCL-6基因。分析其与临床资料、治疗效果和预后的相关性。结果:27例(33.75%)患者存在P53基因缺失,24例(30.00%)患者存在C-VIYC基因的扩增和重排,46例(57.50%)患者存在BCL-6基因的重排。P53缺失、C-MYC重排和扩增及BCL-6重排与患者的临床分期、疗效和预后具有显著的相关性(P<0.05)。结论:存在P53、C-MYC和BCL-6基因异常的弥漫性大B细胞淋巴瘤患者的治疗效果和预后都较差。

Objective:To study the clinical significance of P53,C-MYC and BCL-6 abnormality in the patients with diffuse large B cell lymphoma(DLBCL).Methods:From July 2011 to January 2013,80 patients with DLBCL were admitted in our hospital and were chosen as study objects,their clinical data were collected.The abnormality of P53,CMYC and BCL-6 was examined by using I- FISH for all the patients.The correlation of abnormality of P53,C-MYC and BCL-6 with clinical staging,curative efficacy and prognosis of the patients were analyzed.Results:Out of 80 patients 27patients(33.75%) had P53 deletion,24 patients(30.00%) had C-MYC rearrangement/amplification,and 46 patients(57.50%) had BCL-6 rearrange-ment.The P53 deletion,C-MYC rearrangement/amplification and BCL-6rearrangement significantly correlated with staging,curative effect and prognosis of the patients(P < 0.05).Conclusion:The curative efficacy and prognosis of the DLBCL patients with abnormality of P53,C-MYC and BCL-6have been confirmed to be unsatisfactory.